DEVELOPMENT OF STEM CELL-BASED CANCER THERAPY STRATEGIES
Downloads
Cancer remains one of the leading causes of death worldwide, with various treatment options available depending on the type and stage of the disease. Traditional therapies, such as surgery, radiotherapy, chemotherapy, and immunotherapy, have shown varying degrees of success, but each has its limitations. Recently, stem cell therapies have emerged as a promising alternative, offering more targeted treatments with fewer side effects. Stem cells, including mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and cancer stem cells (CSCs), have demonstrated potential in cancer therapy through mechanisms like tumor site targeting, paracrine signaling, and gene delivery. MSCs, in particular, are of interest due to their ability to migrate to tumor sites and release exosomes that can influence tumor growth, angiogenesis, and metastasis. Modified MSCs have been engineered to deliver anticancer agents or "suicide" genes, providing a more focused approach to tumor treatment. Moreover, MSCs have shown promise in addressing challenges like drug resistance and recurrence in cancer. However, their effectiveness depends on factors such as exosome composition and the tumor microenvironment. Despite the challenges, stem cell-based therapies, including MSC-derived exosomes, represent a novel strategy to enhance the specificity and efficacy of cancer treatments. This review explores current advances in stem cell-based cancer therapies, highlighting their potential, ongoing research, and the need for further studies to optimize these approaches for clinical application.
Aldoghachi, A. F., Chong, Z. X., Yeap, S. K., Cheong, S. K., Ho, W. Y. and Ong, A. H. K. (2023), “Stem Cells for Cancer Therapy: Translating the Uncertainties and Possibilities of Stem Cell Properties into Opportunities for Effective Cancer Therapy”, International Journal of Molecular Sciences, Vol. 24 No. 2, pp. 1012.
Aravindhan, S., Ejam, S. S., Lafta, M. H., Markov, A., Yumashev, A. V. and Ahmadi, M. (2021), “Mesenchymal stem cells and cancer therapy: insights into targeting the tumour vasculature”, Cancer Cell International, Vol. 21 No. 1, pp. 158.
Bhaumik, S. (2011), “Advances in imaging gene-directed enzyme prodrug therapy”, Current Pharmaceutical Biotechnology, Vol. 12 No. 4, pp. 497-507.
Chang, J. C. (2016), “Cancer stem cells Role in tumor growth, recurrence, metastasis, and treatment resistance”, Medicine, Vol. 95, pp. S20-S25.
Choi, Y., Lee, H. K. and Choi, K. (2023), “Engineered adult stem cells: a promising tool for anti-cancer therapy”, BMB Reports, Vol. 56 No. 2, pp. 71-7.
Chu, D., Nguyen, T. T., Tien, N. L. B., Tran, D., Jeong, J., Anh, P. G., Thanh, V. V., Truong, D. T. and Dinh, T. C. (2020), “Recent Progress of Stem Cell Therapy in Cancer Treatment: Molecular Mechanisms and Potential Applications”, Cells, Vol. 9 No. 3, pp. 563.
Copelan, E. A. (2006), “Hematopoietic stem-cell transplantation”, The New England Journal of Medicine, Vol. 354 No. 17, pp. 1813-26.
Danks, M. K. and Potter, P. M. (2004), “Enzyme-prodrug systems: carboxylesterase/CPT-11”, Methods in Molecular Medicine, Vol. 90, pp. 247-62.
Ghaedi, M., Soleimani, M., Taghvaie, N. M., Sheikhfatollahi, M., Azadmanesh, K., Lotfi, A. S. and Wu, J. (2011), “Mesenchymal stem cells as vehicles for targeted delivery of anti-angiogenic protein to solid tumors”, The Journal of Gene Medicine, Vol. 13 No. 3, pp. 171-80.
Gomes, J. P. A., Assoni, A. F., Pelatti, M., Coatti, G., Okamoto, O. K. and Zatz, M. (2017), “Deepening a Simple Question: Can MSCs Be Used to Treat Cancer?”, Anticancer Research, Vol. 37 No. 9, pp. 4747-58.
Guescini, M., Genedani, S., Stocchi, V. and Agnati, L. F. (2010), “Astrocytes and Glioblastoma cells release exosomes carrying mtDNA”, Journal of neural transmission, Vol. 117 No. 1, pp. 1-4.
Gutova, M., Flores, L., Adhikarla, V., Tsaturyan L., Tirughana, R., Aramburo, S., Metz, M., Gonzaga, J., Annala, A., Synold, T. W., Portnow, J., Rockne, R. C. and Aboody, K. S. (2019), “Quantitative Evaluation of Intraventricular Delivery of Therapeutic Neural Stem Cells to Orthotopic Glioma”, Frontiers in Oncology, Vol. 9.
Jain, R. K., di Tomaso, E., Duda, D. G., Loeffler, J. S., Sorensen, A. G. and Batchelor, T. T. (2007), “Angiogenesis in brain tumours”, Nature Reviews. Neuroscience, Vol. 8 No. 8, pp. 610-22.
Kanojia, D., Balyasnikova, I. V., Morshed, R. A., Frank, R. T., Yu, D., Zhang, L., Spencer, D. A., Kim, J. W., Han, Y., Yu, D., Ahmed, A. U., Aboody, K. S. and Lesniak, M. S. (2015), “Neural Stem Cells Secreting Anti-HER2 Antibody Improve Survival in a Preclinical Model of HER2 Overexpressing Breast Cancer Brain Metastases”, Stem Cells, Vol. 33 No. 10, pp. 2985-94.
Khiatah, B., Qi, M., Du, W., T-Chen, K., van Megen, K. M., Perez, R. G., Isenberg, J. S., Kandeel, F., Roep, B. O., Ku, H. T. and Al-Abdullah, I. H. (2019), “Intra-pancreatic tissue-derived mesenchymal stromal cells: a promising therapeutic potential with anti-inflammatory and pro-angiogenic profiles”, Stem Cell Research & Therapy, Vol. 10 No. 1, pp. 322.
Knoor, D. A., Ni, Z., Hermanson, D., Hexum, M. K., Bendzick, L., Cooper, L. J. N., Lee, D. A. and Kaufman, S. (2013), “Clinical-Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy”, Stem Cells Translational Medicine, Vol. 2 No. 4, pp. 274-83.
Ko, T., Lin, J., Hu, C., Hsu, Y., Wang, A. H. and Liaw, S. (2003), “Crystal structure of yeast cytosine deaminase. Insights into enzyme mechanism and evolution”, The Journal Biological Chemistry, Vol. 278 No. 21, pp. 19111-7.
Lin, W., Huang, L., Li, Y., Fang, B., Li, G., Chen L. and Xu, L. (2019), “Mesenchymal Stem Cells and Cancer: Clinical Challenges and Opportunities”, BioMed Research International, Vol. 2019.
Neviani, P. and Fabbri, M. (2015), “Exosomic microRNAs in the tumor microenvironment”, Frontiers in Medicine, Vol. 2 No. 47.
Raposo, G. and Stoorvogel, W. (2013), “Extracellular vesicles: Exosomes, microvesicles, and friends”, The Journal of Cell Biology, Vol. 200 No. 4, pp. 373-83.
Ratajczak, J., Miekus, K., Kucia, M., Zhang, J., Reca, R., Dvorak, P. and Ratajczak, M. Z. (2006), “Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery”, Leukemia, Vol. 20 No. 5, pp. 847-56.
Ruella, M. and Kenderian, S. S. (2017), “Next Generation Chimeric Antigen Receptor T Cell Therapy: Going off the Shelf”, BioDrugs, Vol. 31 No. 6, pp. 473-81.
Siegel, R. L., Miller, K. D. and Jemal, A. (2016), “Cancer Statistics, 2016”, CA: A Cancer Journal for Clinicians, Vol. 66 No. 1, pp. 7-30.
Takahashi, K. and Yamanaka, S. (2006), “Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors”, Cell, Vol. 126 No. 4, pp. 663-76.
Wang, C., Natsume, A., Lee, H. J., Motomura, K., Nishimira, Y., Ohno, M., Ito, M., Kinjo, S., Momota, H., Iwami, K., Ohka, F., Wakabayashi, T. and Kim, S. U. (2012), “Neural stem cell-based dual suicide gene delivery for metastatic brain tumors”, Cancer Gene Therapy, Vol. 19 No. 11, pp. 796-801.
Zheng, L., Zhang, D., Chen, X., Yang, L., Wei, Y. and Zhao, X. (2012), “Antitumor activities of human placenta-derived mesenchymal stem cells expressing endostatin on ovarian cancer”, PloS One, Vol. 7 No. 7.
Copyright (c) 2024 Journal of Stem Cell Research and Tissue Engineering
This work is licensed under a Creative Commons Attribution 4.0 International License.
1. As an author you (or your employer or institution) may do the following:
- make copies (print or electronic) of the article for your own personal use, including for your own classroom teaching use;
- make copies and distribute such copies (including through e-mail) of the article to research colleagues, for the personal use by such colleagues (but not commercially or systematically, e.g. via an e-mail list or list server);
- present the article at a meeting or conference and to distribute copies of the article to the delegates attending such meeting;
- for your employer, if the article is a ‘work for hire', made within the scope of your employment, your employer may use all or part of the information in the article for other intra-company use (e.g. training);
- retain patent and trademark rights and rights to any process, procedure, or article of manufacture described in the article;
- include the article in full or in part in a thesis or dissertation (provided that this is not to be published commercially);
- use the article or any part thereof in a printed compilation of your works, such as collected writings or lecture notes (subsequent to publication of the article in the journal); and prepare other derivative works, to extend the article into book-length form, or to otherwise re-use portions or excerpts in other works, with full acknowledgement of its original publication in the journal;
- may reproduce or authorize others to reproduce the article, material extracted from the article, or derivative works for the author's personal use or for company use, provided that the source and the copyright notice are indicated, the copies are not used in any way that implies JSCRTE endorsement of a product or service of any employer, and the copies themselves are not offered for sale.
All copies, print or electronic, or other use of the paper or article must include the appropriate bibliographic citation for the article's publication in the journal.
2. Requests from third parties
Although authors are permitted to re-use all or portions of the article in other works, this does not include granting third-party requests for reprinting, republishing, or other types of re-use. Requests for all uses not included above, including the authorization of third parties to reproduce or otherwise use all or part of the article (including figures and tables), should be referred to JSCRTE by going to our website at http://e-journal.unair.ac.id/index.php/JSCRTE
3. Author Online Use
- Personal Servers. Authors and/or their employers shall have the right to post the accepted version of articles pre-print version of the article, or revised personal version of the final text of the article (to reflect changes made in the peer review and editing process) on their own personal servers or the servers of their institutions or employers without permission from JSCRTE, provided that the posted version includes a prominently displayed JSCRTE copyright notice and, when published, a full citation to the original publication, including a link to the article abstract in the journal homepage. Authors shall not post the final, published versions of their papers;
- Classroom or Internal Training Use. An author is expressly permitted to post any portion of the accepted version of his/her own articles on the author's personal web site or the servers of the author's institution or company in connection with the author's teaching, training, or work responsibilities, provided that the appropriate copyright, credit, and reuse notices appear prominently with the posted material. Examples of permitted uses are lecture materials, course packs, e-reserves, conference presentations, or in-house training courses;
- Electronic Preprints. Before submitting an article to an JSCRTE, authors frequently post their manuscripts to their own web site, their employer's site, or to another server that invites constructive comment from colleagues. Upon submission of an article to JSCRTE, an author is required to transfer copyright in the article to JSCRTE, and the author must update any previously posted version of the article with a prominently displayed JSCRTE copyright notice. Upon publication of an article by the JSCRTE, the author must replace any previously posted electronic versions of the article with either (1) the full citation to the work with a Digital Object Identifier (DOI) or link to the article abstract in JSCRTE homepage, or (2) the accepted version only (not the final, published version), including the JSCRTE copyright notice and full citation, with a link to the final, published article in journal homepage.
4. Articles in Press (AiP) service
JSCRTE may choose to publish an abstract or portions of the paper before we publish it in the journal. Please contact our Production department immediately if you do not want us to make any such prior publication for any reason, including disclosure of a patentable invention.
5. Author/Employer Rights
If you are employed and prepared the article on a subject within the scope of your employment, the copyright in the article belongs to your employer as a work-for-hire. In that case, JSCRTE assumes that when you sign this Form, you are authorized to do so by your employer and that your employer has consented to the transfer of copyright, to the representation and warranty of publication rights, and to all other terms and conditions of this Form. If such authorization and consent has not been given to you, an authorized representative of your employer should sign this Form as the Author.
6. JSCRTE Copyright Ownership
It is the formal policy of JSCRTE to own the copyrights to all copyrightable material in its technical publications and to the individual contributions contained therein, in order to protect the interests of the JSCRTE, its authors and their employers, and, at the same time, to facilitate the appropriate re-use of this material by others. JSCRTE distributes its technical publications throughout the world and does so by various means such as hard copy, microfiche, microfilm, and electronic media. It also abstracts and may translate its publications, and articles contained therein, for inclusion in various compendiums, collective works, databases and similar publications
Every accepted manuscript should be accompanied by "Copyright Transfer Agreement" prior to the article publication.
